Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
Filed with SSE · · 5 pages · Chinese
Release
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. on 6ix
Earlier from Shanghai Fudan Zhangjiang Bio Pharmaceutical
- Announcement on Changing Some Investment Projects Financed by Raised Funds
- Announcement on Amending the Articles of Association and Its Annexes and Canceling the Board of Supervisors
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on the Voluntary Disclosure of Non-Approval of the Marketing Authorization Application for Obeticholic Acid Tablets for the Treatment of Primary Biliary Cholangitis
- Announcement on Result of Shareholding Reduction by Shareholder
Later from Shanghai Fudan Zhangjiang Bio Pharmaceutical
- Announcement on Cancellation of Board of Supervisors and Election of Employee Director for the 8th Board of Directors
- Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Application Acceptance Notice for FZ-P001 Sodium Injection for Intraoperative Visualization of Malignant Lesions in Known or Suspected Lung Cancer Patients
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares
- Announcement on the Acceptance of the Drug Marketing Application for Aminolevulinic Acid Hydrochloride Powder for Oral Solution for Visualization in Glioma Surgery
Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical